In the wake of the RACE Act, identifying and partnering with key stakeholders, namely patient organizations and academia, will enable companies to efficiently overcome key barriers.
This whitepaper offers a high-level orientation around the key barriers to readiness and critical success factors for companies navigating the pediatric oncology space. The primary focus of this whitepaper is on how collaboration with patient organizations will be critical to overcoming the obstacles most companies will encounter.
Together, the elements of this whitepaper aim to support collaboration between industry and patient organizations as a valuable strategy to ensuing readiness for the RACE Act.
Scott Schliebner, Senior Vice President of the Center for Rare Diseases
We measure our HQ with actions, experiences, and intentions. Nowhere is that more evident that in the stories of our subject matter experts. We want…
LLS PedAL: How Collaboration in Pediatric Oncology Trials Will Lead to Success
PRA has partnered with The Leukemia and Lymphoma Society (LLS) on a global precision medicine clinical trial for children with relapsed acute…